Clinical Trials Logo

Smoking Reduction clinical trials

View clinical trials related to Smoking Reduction.

Filter by:

NCT ID: NCT04783857 Recruiting - Smoking Cessation Clinical Trials

Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children

Start date: April 14, 2022
Phase: Phase 4
Study type: Interventional

The investigators aim to address the following specific aims: - Determine the efficacy of Prog in preventing postpartum smoking relapse and reducing smoking relapse risk factors. - Examine the effects of this maternal smoking intervention on infant health. - Examine racial and ethnic differences in intervention outcomes.

NCT ID: NCT04620915 Recruiting - Cancer Clinical Trials

Construal Level as a Novel Pathway for Affect Regulation and Cancer Control

Start date: October 11, 2021
Phase: N/A
Study type: Interventional

The objective of the proposed research is to conduct a longitudinal experiment on the neurocognitive pathways and individual differences in high-level construal for affect regulation and smoking cessation. The population is adult smokers aged 25-55 who have tried and failed to quit and who are experiencing poverty. The primary endpoints are (a) the similarity in neural representation of high-level construal to one of two candidate pathways, (b) the presence of meaningful individual differences in the neural representation of high-level construal, and (c) as a secondary endpoint, the effect size of the high-level construal condition on smoking as measured by cigarettes per day. Each of these endpoints corresponds to a specific null hypothesis. The null hypothesis for the first endpoint is that high-level construal is not significantly different in its neural representation from down-regulation of craving, which would suggest that high-level construal does not operate through distinct mechanisms from traditional treatments. The null hypothesis for the second endpoint is that the between-subjects variability in the neural representation of construal level does not significantly relate to relevant individual differences measures (e.g., traits, task behavior), which would suggest that individual differences are not meaningfully related to outcomes. Finally, the null hypothesis for the secondary endpoint is that the magnitude of the effect of high-level construal on smoking as measured by reductions in average cigarettes per day is not significantly greater than in the other conditions, which would suggest that the efficacy of the high-level construal condition is not significantly greater than a standard text-messaging intervention. The primary endpoints will be assessed at baseline and change from pre-to-post training (8 weeks).